Dr. Reis-Filho will shape portfolio and company-building strategy at the convergence of AI, machine learning and life sciences
He joins from AstraZeneca where he served as Chief of AI for Science Innovation, Enterprise AI, leading initiatives to transform drug discovery and clinical development through AI
SAN FRANCISCO & BOSTON–(BUSINESS WIRE)–Foresite Labs today announced the appointment of Dr. Jorge Reis-Filho as Chief Strategy Officer and Operating Partner. He will also join Foresite Capital as a Venture Partner. Dr. Reis-Filho will join the company’s senior leadership team to help translate advances in AI, machine learning, statistical genetics, data science, and biology into differentiated technologies, platforms, products, and new companies, while providing strategic and operational oversight across venture formation, governance, team building, financing, and growth. Created in 2019, Foresite Labs’ mission is to support the next generation of entrepreneurs who are building transformative companies utilizing AI and data science.
Prior to joining Foresite Labs, Dr. Reis-Filho was Chief of AI for Science Innovation, Enterprise AI at AstraZeneca, where he led initiatives to transform drug discovery and clinical development through AI, including the development of foundation models and agentic frameworks. Dr. Reis-Filho previously served as Chief AI and Data Scientist for Oncology R&D and Vice President of Cancer Biomarker Development at AstraZeneca, leading the creation and clinical validation of biomarkers used to match patients with optimal treatments. Before AstraZeneca, he was Chief of Experimental Pathology at Memorial Sloan Kettering Cancer Center, where he applied genomic technologies, big data analytics, and AI to bridge academic research and commercial innovation.
Dr. Reis-Filho is an expert in molecular pathology, bioinformatics, functional genomics and AI. His work has been recognized with honors including the CRUK Future Leaders Prize, the BCRF Larry Norton Award, and the William Gerald Award from MSKCC. Dr. Reis-Filho earned a joint MD from the University of Porto, Portugal, and the Universidade Federal do Paraná, Brazil; completed histopathology training at the University of Porto; and obtained a PhD in breast cancer molecular pathology from the Institute of Cancer Research and the Royal Marsden Hospital in London, where he rose to Team Leader and subsequently Professor and Chair of Molecular Pathology.
“Jorge brings a rare combination of expertise across drug development, diagnostic and experimental pathology and artificial intelligence. He has spent his career at the forefront of translating advances in computational medicine and AI into real-world impact and validating AI platforms inside one of the world’s leading pharmaceutical companies,” said Jim Tananbaum, co-founder and CEO of Foresite Labs. “That combination of scientific depth and operational experience is exactly what it takes to build enduring companies, and we’re excited to have him bring that expertise to Foresite Labs.”
At Foresite Capital, Dr. Reis-Filho will source and evaluate select opportunities and contribute to investment strategy and decision-making across AIxBio and broader TechBio landscape, building on Foresite Labs’ work incubating companies harnessing emerging technologies to solve complex challenges across industries.
“My career has been driven by translating scientific insights into biomarkers, technologies and therapeutics that transform outcomes for patients, first in academic pathology and, more recently, through building AI platforms within a global biopharmaceutical company,” said Dr. Reis-Filho. “I am immensely excited to bring that experience to Foresite Labs and help build the next generation of enduring companies at the convergence of AI and the biomedical sciences.”
Dr. Reis-Filho’s appointment comes as Foresite Labs’ incubation platform continues to deliver major milestones. In 2024, the company co-incubated Xaira Therapeutics alongside ARCH Venture Partners, which launched with more than $1 billion in committed capital. That same year, Candid Therapeutics launched with $370 million to advance novel T-cell engager therapies for autoimmune disease and was later acquired by UCB for $2.2 billion. Alumis, focused on precision immunology, completed its IPO that same year, and most recently, Foresite Labs co-founded Prometheus, the physical AI company which has since raised more than $12 billion, with ARCH Venture Partners. With his background bridging clinical research, biomarker science, and enterprise AI deployment, Dr. Reis-Filho is expected to play a central role in shaping the next generation of ventures to come out of Foresite Labs.
About Foresite Labs
Foresite Labs creates companies at the intersection of AI/machine learning and science. Using AI, generative AI, and data science, Foresite Labs provides the foundation for bold ideas to take shape and accelerate, ultimately creating a better future for humanity. With headquarters in San Francisco and Boston, the company is building a culture where scientific rigor meets entrepreneurial ambition. To learn more, visit www.foresitelabs.com
Contacts
Media Contact
VSC on behalf of Foresite Labs
[email protected]
